# A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

> **NCT06805825** · PHASE1 · RECRUITING · sponsor: **Novelty Nobility, Inc.** · enrollment: 67 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Small-cell Lung Cancer
- Adenoid Cystic Carcinoma
- Uveal Melanoma
- Neuroendocrine Tumors
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** NN3201

## Key facts

- **NCT ID:** NCT06805825
- **Lead sponsor:** Novelty Nobility, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-03
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06805825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06805825, "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06805825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*